Ubs Oconnor LLC Immunocore Holdings PLC Transaction History

Ubs Oconnor LLC

$1.46 Billion
Q3 2024

A detailed history of Ubs Oconnor LLC transactions in Immunocore Holdings PLC stock. As of the latest transaction made, Ubs Oconnor LLC holds 35,112 shares of IMCR stock, worth $1.05 Million. This represents 0.07% of its overall portfolio holdings.

Number of Shares

35,112

Holding current value

$1.05 Million

% of portfolio

0.07%

11 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2024 Nov 14, 2024	SELL	$30.06 - $41.49 $147,354 - $203,383	-4,902 Reduced 12.25%	35,112 $1.09 Million
Q2 2024 Aug 14, 2024	BUY	$33.78 - $63.75 $374,620 - $706,987	11,090 Added 38.34%	40,014 $1.36 Million
Q1 2024 May 15, 2024	BUY	$60.14 - $75.36 $77,159 - $96,686	1,283 Added 4.64%	28,924 $1.88 Million
Q4 2023 Feb 14, 2024	SELL	$42.85 - $69.5 $501,516 - $813,428	-11,704 Reduced 29.75%	27,641 $1.89 Million
Q3 2023 Nov 14, 2023	SELL	$49.5 - $66.6 $49,500 - $66,600	-1,000 Reduced 2.48%	39,345 $2.04 Million
Q2 2023 Aug 14, 2023	BUY	$48.54 - $61.64 $1.96 Million - $2.49 Million	40,345 New	40,345 $2.42 Billion
Q1 2023 May 15, 2023	BUY	$46.12 - $65.71 $489,471 - $697,380	10,613 Added 28.49%	47,865 $2.37 Million
Q4 2022 Feb 14, 2023	BUY	$45.51 - $65.08 $116,278 - $166,279	2,555 Added 7.36%	37,252 $0
Q3 2022 Nov 14, 2022	SELL	$37.34 - $57.44 $851,352 - $1.31 Million	-22,800 Reduced 39.65%	34,697 $1.63 Billion
Q2 2022 Aug 12, 2022	BUY	$25.46 - $37.72 $496,393 - $735,426	19,497 Added 51.31%	57,497 $2.15 Million
Q1 2022 May 16, 2022	BUY	$18.94 - $34.29 $719,720 - $1.3 Million	38,000 New	38,000 $1.14 Million

Others Institutions Holding IMCR

# of Institutions

135

Shares Held

40.8M

Call Options Held

197K

Put Options Held

451K

View Full List

About Immunocore Holdings plc

Ticker IMCR
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 43,897,100
Market Cap $1.32B
Description
Immunocore Holdings plc, a commercial-stage biotechnology company, engages in the development of immunotherapies for the treatment of cancer, infectious, and autoimmune diseases. The company offers KIMMTRAK for the treatment of patients with unresectable or metastatic uveal melanoma. Its other programs for oncology comprise IMC-C103C that is in ...

More about IMCR

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Ubs Oconnor LLC, based on Form 13F filings with the SEC.

News

Stay updated on Ubs Oconnor LLC with notifications on news.

Account